Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.
about
Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures.Obesity, Type 2 Diabetes and Bone in Adults.Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in JapanBone metabolism after bariatric surgery.Preventive effect of crocin on osteoporosis in an ovariectomized rat model.Divergent effects of obesity on fragility fractures.Role of zoledronic acid in the prevention and treatment of osteoporosis.Subgroup variations in bone mineral density response to zoledronic acid after hip fracture.Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis.A Comprehensive Fracture Prevention Strategy in Older Adults: The European Union Geriatric Medicine Society (EUGMS) Statement.Study on the role of zoledronic acid in treatment of postmenopausal osteoporosis women.Coordinator-based systems for secondary prevention in fragility fracture patients.FRAX(®) with and without bone mineral density.Obesity and bone.Obesity and fracture in men and women: an epidemiologic perspective.Skeletal manifestations of treatment of breast cancer on premenopausal women.Complex association between body weight and fracture risk in postmenopausal women.FRAX and fracture prediction without bone mineral density.Zoledronic Acid (Reclast®, Aclasta®): A Review in Osteoporosis.Obesity and fractures.Obesity is a concern for bone health with aging.Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors.Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study.Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women.Zoledronic acid enhances bone-implant osseointegration more than alendronate and strontium ranelate in ovariectomized rats.Effects of zoledronate versus placebo on spine bone mineral density and microarchitecture assessed by the trabecular bone score in postmenopausal women with osteoporosis: a three-year study.Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX.Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide.The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis.Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort.The PI3K/AKT cell signaling pathway is involved in regulation of osteoporosis.Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis
P2860
Q30236007-63895F16-AA5F-4DA0-A44B-084EB9FA259AQ33571597-1F9D2034-8DAF-423E-997C-5495857190F4Q33841902-B45960C1-01D0-4A6E-9EBD-40B28115C804Q34026645-F1C1B79E-90DA-4299-91A7-FDD08CE24730Q34114117-78843A31-8F67-4ADB-A0D4-B6C2CBC40232Q34273341-BEC6E58C-45BD-43ED-99EE-88D2E4DB99B2Q34984177-1A178A07-101A-443E-8481-0CFA6BC7C66DQ35017673-AD9C2923-AEAE-4315-B73E-58AD163858D2Q35215353-3681F67A-5A65-40F4-B730-1EE8F7C599CEQ36059331-0D2A7B3B-B8D1-4B06-B5A6-9C523D134508Q37392405-AFD9C5D8-CAE5-4510-A443-3FE9A5EB094BQ37526922-E953642F-B87B-4BC4-84DE-EB32D2A362F9Q37879009-8143D92C-0515-4F59-A7EC-EC13F6FF3880Q37953297-1063D35B-0D85-4746-A672-FF37084D1E73Q38071562-ED1BDD68-EECF-4CCA-99D3-D5F0E914AFD5Q38076660-660CBBF8-8B86-4EB8-8F67-36586D7936B9Q38152661-10E68374-A9EA-4035-AC51-33495E5B2432Q38317545-9A035EDD-7076-470B-8D63-82C49881FA24Q38613173-B52C3A36-6333-4839-BF07-9EBC8EFFBAF1Q39013796-378B863F-9DA2-466E-A051-F6670D595FAFQ39138487-9FF506EE-4DE1-488E-BF41-C4D5773683E3Q39224895-14CF9F84-F092-466F-9AA2-45D00177CD7AQ40588003-06F44F10-C6FA-44BF-BC1A-57574AB465E8Q42673018-A6502F91-0C2D-4355-822F-19F2AB99FA7DQ43767729-BF7CBD32-405A-49DD-AA72-45D097759FBBQ43876049-C684F000-5A80-40EA-834C-796E32323C0BQ44688610-B108BCE6-6D4E-4CEC-90A7-1E3DAB4347DEQ44907080-7231DFF8-C57B-4B10-8941-E7A2A295DF51Q49505161-2F6588A8-D91E-4125-A4CD-1CF381DEAE14Q51153117-8C41BB0E-33DC-49BD-825F-CF9F8AB8D919Q51194245-A5809BBD-4813-4998-9DA8-7A0A03C0114EQ53338072-DB8138A7-CE66-4B85-8475-B89111F6DEB0Q58970581-CD1FA573-09D8-406C-BFB3-4789BE7958BF
P2860
Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effect of once-yearly zoledron ...... ral neck bone mineral density.
@en
Effect of once-yearly zoledron ...... ral neck bone mineral density.
@nl
type
label
Effect of once-yearly zoledron ...... ral neck bone mineral density.
@en
Effect of once-yearly zoledron ...... ral neck bone mineral density.
@nl
prefLabel
Effect of once-yearly zoledron ...... ral neck bone mineral density.
@en
Effect of once-yearly zoledron ...... ral neck bone mineral density.
@nl
P2093
P2860
P356
P1476
Effect of once-yearly zoledron ...... ral neck bone mineral density.
@en
P2093
Dennis M Black
Dieter Felsenberg
HORIZON Pivotal Fracture Trial
Lisa Palermo
Peter Mesenbrink
Pierre D Delmas
Richard Eastell
Silvano Adami
Steven Boonen
Steven R Cummings
P2860
P304
P356
10.1210/JC.2008-2765
P407
P577
2009-06-30T00:00:00Z